Evaluation of the efficacy of the continuation electroconvulsive therapy in treatment-resistant schizophrenia

Archives of Clinical Psychiatry (São Paulo)

Isil Gogcegoz Gul¹  Gul Eryilmaz¹  Gokben Hizli Sayar¹  Eylem Ozten¹  Mustafa Murat Arat¹  Nevzat Tarhan¹ 

关键词: Continuation ECT;    schizophrenia treatment-resistant;    PANSS;    BPRS;    ECT de continuação;    esquizofrenia resistente ao tratamento;    PANSS;    BPRS;   

DOI  :  10.1590/0101-60830000000018

来源: SciELO

【 摘 要 】

Background: Electroconvulsive therapy (ECT) has been reported being a safe and effective treatment in schizophrenia. However, there are a limited number of studies assessing continuation ECT utilization in patients with schizophrenia giving partial response to pharmacological treatment. Objective: The aim of this study is to evaluate the effectiveness of continuation ECT in preventing relapse in patients with treatment-resistant schizophrenia. Methods: In this retrospective analysis, schizophrenia patients (n = 73) were defined in three groups such as patients who received only AP treatment (only AP), patients who received acute ECT only during hospitalization (aECT+AP), patients who received acute ECT and continuation ECT (a-cECT+AP). Three groups were compared according to positive and negative syndrome scale (PANSS) and Brief Psychiatric Rating Scale (BPRS) scores. Results: As per comparison of only AP group, aECT+AP group and a+cECT+AP groups in terms of after discharge PANSS and after discharge BPRS scores for 1st month, 3rd month and 6th month; 3rd and 6th month’s PANSS scores of a+cECT+AP group were statistically significantly lower than other two groups. Discussion: Although this study suffers the limitations of retrospective medical chart analysis, results suggest that, in patients with a diagnosis of schizophrenia who have responded to an acute course of ECT, continuation ECT in combination with antipsychotics is more effective than antipsychotics alone in preventing relapse.

【 授权许可】

CC BY   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License